MedChemExpress LLC’s Post

The elevated low-density lipoprotein cholesterol (LDL-C) is a causal risk factor for atherosclerotic cardiovascular disease (ASCVD), and heterozygous familial hypercholesterolemia (HeFH). Cholesteryl ester transfer protein (CETP) transports cholesterol from good high-density lipoprotein cholesterol (HDL-C) to low-density lipoprotein cholesterol (LDL-C). NewAmsterdam’s Obicetrapib is a novel, selective CETP inhibitor to address the limitations of current treatments. Obicetrapib is under investigation in phase III clinical trials as a monotherapy product, and in phase II studies as a fixed dose combination with Ezetimibe. The new analysis from the Phase 2 ROSE2 trial evaluating Obicetrapib in combination with Ezetimibe is presented at 2024 American College of Cardiology Congress. The pivotal Phase 3 PREVAIL global cardiovascular outcome trial enrolls over 9,000 patients. Chemenu supports your scientific research and drug discovery. Check our product catalog: https://lnkd.in/gYKXfHhd   #CETP #Cholesterol #Oral #Inhibitor #LDL #ASCVD #HeFH #Buildingblocks

IBD extraintestinal & joint manifestations - systematic review of 61 studies (13,806 pts) found 8% new joint findings during advanced therapy (no signif difference betw vedolizumab (9%) & ustekinumab (6%).

IBD extraintestinal & joint manifestations - systematic review of 61 studies (13,806 pts) found 8% new joint findings during advanced therapy (no signif difference betw vedolizumab (9%) & ustekinumab (6%).

The exciting news about Kyverna Therapeutics and its treatment for Stiff Person Syndrome continues. The FDA giving KYV-101 RMAT designation, which is a major step forward. Check out this latest article by Melissa Rudy on Fox News Media

Stunning topline results from Merck Winrevair’s Phase 3 ZENITH trial found that the drug significantly reduced morbidity and mortality risks in patients with pulmonary arterial hypertension, paving the way for stronger commercialization and further functional trials. https://lnkd.in/eD2RT9Rc

Liver fibrosis, a key driver of mortality in metabolic dysfunction-associated steatohepatitis, currently lacks approved treatments. However, the MAESTRO-NASH clinical trial offers promising results. Harrison et al. demonstrated that resmetirom, a selective THR-β agonist, effectively treats both metabolic dysfunction-associated steatohepatitis and liver fibrosis after 52 weeks. Read Viewpoint in #Med https://lnkd.in/eWNd_ERh #NAFLD #MASLD #MASH #LiverFibrosis #Resmetirom

In the ESSENCE trial, semaglutide improved liver fibrosis in patients with metabolic dysfunction-associated steatohepatitis (MASH). https://lnkd.in/eJahvCc4

The first patient with #type2diabetes and diabetes-related complications has been enrolled in a #Phase2 randomized #clinicaltrial of approximately 300 patients with elevated blood glucose, #systemicinflammation and at risk for complications of #diabetes, called DAPAN-DIA, with Olatec’s #NLRP3inhibitor, #dapansutrile. DAPAN-DIA represents the first T2D clinical trial of any selective NLRP3 inhibitor in the emerging class that will also assess cardiometabolic and other risk factors beyond anti-hyperglycemic effects including weight lowering efficacy in combination with GLP-1 therapy The study is being conducted as an investigator-sponsored study under Principal Investigator @Marc Donath MD at the University Hospital of Basel in Switzerland, a long-time Olatec collaborator and advisor as well as a leading researcher-clinician in immuno-metabolism. https://lnkd.in/eZ-RuyNr

Lowering the production of apoC-III has been found to decrease fasting triglyceride levels in individuals who lack lipoprotein lipase activity. Read the Viewpoint, published in Med by Cell Press, on the recent phase 3 BALANCE clinical trial examining the impact of olezarsen, a novel antisense oligonucleotide that hinders the expression of apoC-III mRNA, on triglyceride levels and the risk of acute pancreatitis. https://lnkd.in/eyCqA9XF #lipidresearch #triglycerides #pancreatitisprevention #clinicaltrial #BALANCE

🎉 Exciting News in Psoriasis Treatment! 🎉 Boehringer Ingelheim's SPEVIGO injection has received FDA approval for the treatment of generalised pustular psoriasis (GPP), offering new hope for patients battling this challenging condition. The FDA's decision, based on the positive outcomes of the EFFISAYIL 2 clinical trial, marks a significant milestone in psoriasis management. SPEVIGO, a humanised selective IgG1 antibody, targets the interleukin-36 receptor, a key player in the immune system's signalling pathway implicated in the pathogenesis of GPP. Notably, the 48-week EFFISAYIL 2 study demonstrated SPEVIGO's efficacy, with a remarkable 84% reduction in GPP flare risk compared to placebo. Moreover, the high-dose SPEVIGO group showed no flares after week four, highlighting the treatment's potential to provide long-term relief. While SPEVIGO offers promising benefits, it's essential to note the reported adverse events associated with treatment, including reactions at the injection site, urinary tract infections, arthralgia, and pruritus. #PsoriasisTreatment #FDAApproval #HealthcareInnovation #MedicalAdvancements #BoehringerIngelheim #SPEVIGO #GPP #PsoriasisAwareness #PatientCare #psoriasis https://lnkd.in/dMDQ5j9B